| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | H.C. Wainwright bekräftigt Kaufempfehlung für Alto Neuroscience | 2 | Investing.com Deutsch | ||
| 10.11. | Alto Neuroscience GAAP EPS of -$0.54 beats by $0.13 | 1 | Seeking Alpha | ||
| 10.11. | Alto Neuroscience, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11. | Alto Neuroscience, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.11. | Alto Neuroscience, Inc.: Alto Neuroscience Announces Participation in Upcoming Investor Conferences | 297 | Business Wire | Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that... ► Artikel lesen | |
| 20.10. | H.C. Wainwright raises Alto Neuroscience stock price target to $60 | 2 | Investing.com | ||
| 14.10. | Here's Why You Should Add ANRO Stock to Your Portfolio Now | 3 | Zacks | ||
| ALTO NEUROSCIENCE Aktie jetzt für 0€ handeln | |||||
| 23.09. | Alto Neuroscience auf TD Cowen Summit: Pramipexol-Kombination im Fokus | 2 | Investing.com Deutsch | ||
| 28.08. | Alto Neuroscience promotes Nick Smith to president & CFO | 1 | Seeking Alpha | ||
| 27.08. | Alto Neuroscience, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.08. | Alto Neuroscience promotes Nick Smith to president and CFO | 2 | Investing.com | ||
| 18.08. | H.C. Wainwright hebt Kursziel für Alto Neuroscience auf 55 US-Dollar an | 5 | Investing.com Deutsch | ||
| 13.08. | Alto Neuroscience auf Rekordhoch: Aktie klettert auf 32,74 US-Dollar | 13 | Investing.com Deutsch | ||
| 12.08. | Alto Neuroscience GAAP EPS of -$0.65 beats by $0.08 | 1 | Seeking Alpha | ||
| 12.08. | Alto Neuroscience, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.08. | Alto Neuroscience, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | Biotech Stocks At 52-Week Highs - Delcath Systems +22% On Q2 Results, Alto Neuroscience, Hemab Therapeutics, Monopar Therapeutics, Nurix Therapeutics | 1.373 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen | |
| 03.08. | Cool Nature übernimmt ANRO und positioniert sich als führender Maronenerzeuger | 552 | fruchtportal.de | Die Unternehmensgruppe, zu der Cool Farms, der größte Kiwi-Produzent der Iberischen Halbinsel, gehört, plant die Anpflanzung von 2.000 Hektar Maronenbäumen mit einer jährlichen Produktion von 8 Millionen... ► Artikel lesen | |
| 15.07. | Biotech Stocks Hit 52-Week Highs - The Oncology Institute, Inhibikase Therapeutics, Alto Neuroscience, Elevance Health, Privia Health | 1.028 | AFX News | WASHINGTON (dpa-AFX) - These biotech stocks touched a 52-week high on July 14, 2026, attributable to key catalysts like announced offerings to increase capital and the expansion of business... ► Artikel lesen | |
| 13.07. | Alto Neuroscience platziert Aktien im Wert von 100 Mio. US-Dollar zu 26,48 US-Dollar | 1 | Investing.com Deutsch |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,15 | -0,58 % | BioNTech-Aktie: Totes Kapital? | Die Aktie von BioNTech bleibt trotz des rückläufigen Impfstoffgeschäfts ein spannender Titel am Aktienmarkt. Anleger richten ihren Blick zunehmend auf die milliardenschwere Forschungspipeline im Bereich... ► Artikel lesen | |
| AMGEN | 415,95 | -1,11 % | Amgen Announces Positive Phase 3 Results For Dazodalibep In Sjögren's Disease | Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/... ► Artikel lesen | |
| NOVAVAX | 7,200 | -1,77 % | Novavax hebt Prognose an: Worauf es jetzt ankommt | ||
| BIOGEN | 226,05 | -1,29 % | Eisai, Biogen Report Five-Year Leqembi Data Showing Sustained Alzheimer's Benefit | WESTON (dpa-AFX) - Eisai Co., Ltd. (4523.T) and Biogen Inc. (BIIB) presented long-term data from the Phase 3 Clarity AD trial showing that continuous treatment with LEQEMBI (lecanemab-irmb)... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 868,70 | +0,28 % | Bayer, Roche und Regeneron: Wie Big-Pharma den Milliardenmarkt der Netzhauterkrankungen umkämpfen | ||
| VIKING THERAPEUTICS | 24,600 | +0,82 % | Viking Therapeutics gains amid report of renewed takeover interest | ||
| INTELLIA THERAPEUTICS | 8,920 | -0,45 % | Intellia auf der Jefferies Global Healthcare Conference: Marktstart und Pipeline im Fokus | ||
| TEMPUS AI | 57,74 | -1,95 % | Cathie Wood's weekly recap: boosts Nvidia, CoreWeave, Archer Aviation; pares Tempus AI, Palantir | ||
| BIOCRYST PHARMACEUTICALS | 6,796 | +0,09 % | BioCryst presents real-world data on ORLADEYO at ACAAI meeting | ||
| BIOMARIN PHARMACEUTICAL | 52,96 | +0,38 % | 50 Prozent der neuen US-Arzneien waren Orphan Drugs: Warum BioMarin, Vertex und NurExone kleine Märkte anders entwickeln | ||
| EXELIXIS | 62,01 | +1,61 % | Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything | ||
| SAREPTA THERAPEUTICS | 13,380 | -2,76 % | Sarepta Therapeutics auf Guggenheim-Konferenz: Starker Cashflow finanziert breite Entwicklungspipeline | ||
| CARDIOL THERAPEUTICS | 0,883 | -1,01 % | Cardiol Therapeutics GAAP EPS of -C$0.11 misses by C$0.03 | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,653 | -0,45 % | Pacific BioSciences of California (NDQ:PACB): After a Horror 2 Years, Is This Company About To Reach Its Inflection Point | ||
| VAXART | 0,600 | 0,00 % | Vaxart, Inc.: Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology | European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart's Norovirus vaccine program through at least 2036 across key European marketsKEY HIGHLIGHTS:•... ► Artikel lesen |